Annual report pursuant to Section 13 and 15(d)

GENERAL ORGANIZATION AND BUSINESS (Details Narrative)

v3.19.1
GENERAL ORGANIZATION AND BUSINESS (Details Narrative)
12 Months Ended
Apr. 12, 2019
USD ($)
Feb. 12, 2018
Number
shares
Feb. 02, 2018
shares
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Nov. 10, 2011
USD ($)
Common stock issued to shareholders       $ 1,250,000  
Accumulated deficit       (23,412,269) (19,811,052)  
Net cash used in operating activities       (883,841) (1,275,202)  
Cash in hand       12,500    
Note payable related party       758,257 $ 277,820  
Face amount       174,500    
Subsequent Event [Member]            
Advance from related parties $ 339,144          
CJY Holdings, Ltd [Member]            
Face amount       305,937    
Series A Preferred Stock [Member]            
Gross proceeds from private placements       $ 275,000    
Number of shares issued | shares     27,500      
Contribution Agreement [Member] | CureDM Group Holdings, LLC [Member]            
Number of shares issued | shares   47,741,140        
Number of shares issued at time of delivered | shares   25,000,000        
Number of shares issued at time of milestone | shares   22,741,140        
Number of shares issued per tranche | shares   5,685,285        
Number of tranches for delivered | Number   4        
Agreement and Plan of Merger Member [Member] | Boston Therapeutics, Inc. [Member]            
Common stock issued to shareholders           $ 4,000,000
Percentage of outstanding common stock           100.00%